Showing results (1-10 of 18) with videos related to
Sort By:
Pageof 2
Drug Safety|September 11, 2015
A Note on the Validity and Reliability of Multi-Criteria Decision Analysis for the Benefit-Risk Assessment of MedicinesAlberto Garcia-HernandezJournal of Biopharmaceutical Statistics|April 14, 2026
A geometrically intuitive framework for the synthesis method in non-inferiority trialsAlberto Garcia-Hernandez, Paul MeyvischJournal of Nephrology|June 8, 2023
Clinical factors for predicting cardiovascular risk, need for renal replacement therapy, and mortality in patients with non-dialysis-dependent stage 3-5 chronic kidney disease from the Salford Kidney StudyAna Filipa Alexandre, Matthias Stoelzel, Amit Kiran, et al.Journal of Pharmacokinetics and Pharmacodynamics|September 15, 2020
Population pharmacokinetics and pharmacodynamics of a novel vascular adhesion protein-1 inhibitor using a multiple-target mediated drug disposition modelNelleke Snelder, Sven Hoefman, Alberto Garcia-Hernandez, et al.European Journal of Drug Metabolism and Pharmacokinetics|June 12, 2013
Darexaban (YM150), an oral direct factor Xa inhibitor, has no effect on the pharmacokinetics of digoxinTakeshi Kadokura, Dorien Groenendaal, Marten Heeringa, et al.Biopharmaceutics & Drug Disposition|August 10, 2013
Clinical pharmacokinetics, pharmacodynamics, safety and tolerability of darexaban, an oral direct factor Xa inhibitor, in healthy Caucasian and Japanese subjectsTakeshi Kadokura, Makoto Kashiwa, Dorien Groenendaal, et al.Clinical Pharmacology in Drug Development|April 30, 2016
The pharmacokinetics of darexaban (YM150), an oral direct factor Xa inhibitor, are not affected by ketoconazole, a strong inhibitor of CYP3A and P-glycoproteinDorien Groenendaal, Gregory Strabach, Alberto Garcia-Hernandez, et al.British Journal of Clinical Pharmacology|May 31, 2012
The pharmacokinetics of darexaban are not affected to a clinically relevant degree by rifampicin, a strong inducer of P-glycoprotein and CYP3A4Dorien Groenendaal, Gregory Strabach, Alberto Garcia-Hernandez, et al.Journal of Pharmacokinetics and Pharmacodynamics|September 15, 2020
Mechanism-based modeling of the effect of a novel inhibitor of vascular adhesion protein-1 on albuminuria and renal function markers in patients with diabetic kidney diseaseSven Hoefman, Nelleke Snelder, Martijn van Noort, et al.Advances in Therapy|October 28, 2017
Pharmacokinetic Evaluation of the Interactions of Amenamevir (ASP2151) with Ketoconazole, Rifampicin, Midazolam, and Warfarin in Healthy AdultsTomohiro Kusawake, Martin den Adel, Dorien Groenendaal-van de Meent, et al.Pageof 2